| Central carbon metabolism in cancer |
1.79 |
2.30e-1 |
67/70 (95.71%) |
PIK3R1;MET;PFKL;...
|
| DNA replication |
1.75 |
1.86e-1 |
34/36 (94.44%) |
RFC3;RPA2;MCM3;...
|
| Starch and sucrose metabolism |
1.69 |
2.12e-1 |
25/36 (69.44%) |
GPI;PYGB;AGL;...
|
| Glycolysis / Gluconeogenesis |
1.64 |
2.19e-1 |
56/67 (83.58%) |
GPI;ALDH2;GAPDH;...
|
| Allograft rejection |
1.64 |
1.84e-1 |
32/38 (84.21%) |
CD40;HLA-DQB1;HLA-DPB1;...
|
| Mismatch repair |
1.61 |
2.01e-1 |
22/23 (95.65%) |
RFC3;RPA2;MLH1;...
|
| Galactose metabolism |
1.60 |
1.85e-1 |
26/31 (83.87%) |
GALE;PFKL;AKR1B1;...
|
| Fanconi anemia pathway |
1.58 |
2.00e-1 |
36/54 (66.67%) |
HES1;FAAP100;RPA2;...
|
| Pentose phosphate pathway |
1.57 |
1.85e-1 |
25/30 (83.33%) |
GPI;PFKL;G6PD;...
|
| Intestinal immune network for IgA production |
1.54 |
2.14e-1 |
38/48 (79.17%) |
TGFB1;CD40;HLA-DQB1;...
|
| Primary immunodeficiency |
1.53 |
2.11e-1 |
33/38 (86.84%) |
CD40;IGLL1;IL7R;...
|
| Asthma |
1.48 |
3.04e-1 |
25/31 (80.65%) |
CD40;HLA-DQB1;HLA-DPB1;...
|
| Taste transduction |
1.48 |
2.81e-1 |
61/86 (70.93%) |
PRKACB;SCN3A;CACNA1A;...
|
| Herpes simplex virus 1 infection |
1.46 |
3.05e-1 |
165/498 (33.13%) |
PIK3R1;TRAF5;PILRB;...
|
| Mucin type O-glycan biosynthesis |
1.45 |
3.13e-1 |
20/36 (55.56%) |
GALNT7;GALNT12;GALNT14;...
|
| Lysine degradation |
1.45 |
3.03e-1 |
51/63 (80.95%) |
ALDH2;DLD;KMT5B;...
|
| Spliceosome |
1.44 |
2.91e-1 |
101/150 (67.33%) |
SF3B3;PRPF4;PPIE;...
|
| N-Glycan biosynthesis |
1.44 |
2.82e-1 |
38/50 (76%) |
GANAB;DPM3;MGAT2;...
|
| mRNA surveillance pathway |
1.43 |
2.76e-1 |
71/98 (72.45%) |
SMG7;RNPS1;PAPOLG;...
|
| Homologous recombination |
1.43 |
2.69e-1 |
35/41 (85.37%) |
RAD54B;RPA2;POLD4;...
|
| Mannose type O-glycan biosynthesis |
1.42 |
2.77e-1 |
14/23 (60.87%) |
B4GALT2;RXYLT1;POMGNT1;...
|
| Pyrimidine metabolism |
1.40 |
2.96e-1 |
40/56 (71.43%) |
NME4;NT5E;CTPS1;...
|
| Type II diabetes mellitus |
1.39 |
3.06e-1 |
42/46 (91.3%) |
PIK3R1;SOCS2;CACNA1A;...
|
| Nicotine addiction |
1.35 |
4.04e-1 |
32/40 (80%) |
GRIA2;CACNA1A;GABRP;...
|
| Base excision repair |
1.33 |
4.29e-1 |
29/33 (87.88%) |
POLD4;FEN1;SMUG1;...
|
| Viral carcinogenesis |
1.33 |
4.34e-1 |
149/203 (73.4%) |
DNAJA3;USP7;PIK3R1;...
|
| Acute myeloid leukemia |
1.29 |
4.41e-1 |
66/67 (98.51%) |
PIK3R1;PIK3CD;DUSP6;...
|
| Malaria |
1.29 |
4.35e-1 |
44/50 (88%) |
TGFB1;MET;CD40;...
|
| Regulation of actin cytoskeleton |
1.28 |
4.29e-1 |
185/218 (84.86%) |
PIK3R1;ACTN4;PDGFRA;...
|
| B cell receptor signaling pathway |
1.27 |
4.44e-1 |
71/81 (87.65%) |
PIK3R1;PIK3CD;CR2;...
|
| Pathways of neurodegeneration |
-1.34 |
3.38e-1 |
354/475 (74.53%) |
MAPK3;RYR1;DNAI2;...
|
| Kaposi sarcoma-associated herpesvirus infection |
-1.37 |
2.78e-1 |
172/193 (89.12%) |
CLEC2B;GNG5;JAK2;...
|
| Insulin resistance |
-1.38 |
2.51e-1 |
96/108 (88.89%) |
SLC2A2;ACACB;IL6;...
|
| Parkinson disease |
-1.38 |
2.58e-1 |
176/249 (70.68%) |
NDUFA8;MAPK8;SLC18A2;...
|
| Primary bile acid biosynthesis |
-1.41 |
2.28e-1 |
15/17 (88.24%) |
AMACR;SCP2;BAAT;...
|
| Coronavirus disease |
-1.41 |
2.36e-1 |
215/232 (92.67%) |
RPL14;ADAM17;C6;...
|
| Linoleic acid metabolism |
-1.41 |
2.38e-1 |
21/29 (72.41%) |
PLA2G5;CYP2E1;CYP2C9;...
|
| Mineral absorption |
-1.42 |
2.32e-1 |
48/60 (80%) |
MT1E;MT1X;ATP1A1;...
|
| Nitrogen metabolism |
-1.42 |
2.42e-1 |
16/17 (94.12%) |
CPS1;CA14;GLUD2;...
|
| Vascular smooth muscle contraction |
-1.42 |
2.52e-1 |
113/133 (84.96%) |
PLA2G5;CALCRL;GNA11;...
|
| Aldosterone synthesis and secretion |
-1.43 |
2.52e-1 |
85/98 (86.73%) |
NR4A1;ATP1A1;ATP1B3;...
|
| Legionellosis |
-1.44 |
2.51e-1 |
51/57 (89.47%) |
EEF1A2;HSPA2;TLR5;...
|
| Cardiac muscle contraction |
-1.44 |
2.61e-1 |
64/87 (73.56%) |
CACNA1S;TNNT2;CACNG1;...
|
| Ether lipid metabolism |
-1.45 |
2.57e-1 |
32/49 (65.31%) |
PLA2G4C;PLD2;PLA2G3;...
|
| Sphingolipid metabolism |
-1.45 |
2.63e-1 |
32/49 (65.31%) |
SMPD3;PLPP1;SMPD2;...
|
| IL-17 signaling pathway |
-1.46 |
2.69e-1 |
84/94 (89.36%) |
TRAF4;CXCL2;HSP90AB1;...
|
| Bladder cancer |
-1.46 |
2.67e-1 |
40/41 (97.56%) |
DAPK1;MYC;RPS6KA5;...
|
| Pertussis |
-1.51 |
1.97e-1 |
64/76 (84.21%) |
MAPK3;NOD1;CXCL6;...
|
| Fatty acid elongation |
-1.52 |
2.04e-1 |
19/27 (70.37%) |
ELOVL4;HADHA;PPT2;...
|
| Terpenoid backbone biosynthesis |
-1.56 |
1.68e-1 |
18/22 (81.82%) |
HMGCR;MVK;FNTB;...
|
| Complement and coagulation cascades |
-1.58 |
1.45e-1 |
76/85 (89.41%) |
C2;F10;C8G;...
|
| cGMP-PKG signaling pathway |
-1.59 |
1.41e-1 |
145/167 (86.83%) |
ADRB3;ADRA1D;GNA13;...
|
| Renin-angiotensin system |
-1.60 |
1.51e-1 |
20/23 (86.96%) |
CPA3;ENPEP;AGT;...
|
| Retinol metabolism |
-1.61 |
1.53e-1 |
41/68 (60.29%) |
HSD17B6;ADH1B;DHRS3;...
|
| PPAR signaling pathway |
-1.62 |
1.60e-1 |
66/74 (89.19%) |
SCD5;RXRG;ACSL3;...
|
| Steroid biosynthesis |
-1.65 |
1.67e-1 |
19/20 (95%) |
DHCR7;SQLE;SOAT1;...
|
| Arginine biosynthesis |
-1.66 |
1.99e-1 |
17/22 (77.27%) |
CPS1;OTC;GLUD2;...
|
| Steroid hormone biosynthesis |
-1.70 |
1.49e-1 |
43/61 (70.49%) |
SULT2B1;CYP11A1;CYP3A7;...
|
| Biosynthesis of unsaturated fatty acids |
-1.74 |
1.51e-1 |
21/27 (77.78%) |
HSD17B4;SCD5;ELOVL4;...
|
| Ovarian steroidogenesis |
-1.80 |
1.01e-1 |
41/51 (80.39%) |
HSD17B1;CYP1B1;CYP1A1;...
|
